Lundbeck silent on shutdown of Indian operations

Despite a complete withdrawal from the market of one of the world's most populous nations, the Danish pharmaceutical giant doesn't want to comment on the reason why, or whether any other domestic operations are facing closedowns.

Lundbeck's interest in the Indian market has suffered a blow, but the company doesn't want to say why it is suddenly ceasing operations completely. | Photo: Foto af Ulrich Quistgaard

With over 1.3 billion people, India should, on the face of it, appear an attractive drug market for life science firms. Nonetheless, Lundbeck has decided to cease its operations in the Central Asian country completely.

The company doesn't want to reveal what precisely led to this development.

Read the whole article

Get 14 days free access.
No credit card required.

An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Lundbeck chairman demands change: "We can't live with this"

Years of work developing new treatments at Lundbeck has so far come to nothing. This has led chairman Lars Rasmusssen to demand visible results, even though CEO Deborah Dunsire has essentially had to restart development work since she joined the firm in 2018.

Eli Lilly upgrades earnings per share guidance

On Tuesday, US-based pharmaceutical firm Eli Lilly has updated elements of its 2021 financial guidance pertaining to earnings per share (non-GAAP), now expecting USD 7.95-8.05 compared to the previous USD 7.8-8.

Further reading

Related articles

Trial banner

Latest news

See all jobs